Composition:
Dasatinib 50 mg
Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase.
Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
Adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) with resistance or intolerance to prior therapy.
Paediatric patients 1 year of age and older with Ph+ CML in chronic phase.
Paediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
*To be consumed as directed by physician.
